Perspective Therapeutics, Inc. (NYSE:CATX) Receives $12.56 Average Price Target from Analysts

Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have been given an average recommendation of "Buy" by the eleven research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $12.56.

CATX has been the subject of a number of recent analyst reports. Truist Financial decreased their target price on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Royal Bank Of Canada upgraded shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and raised their target price for the company from $15.00 to $16.00 in a research note on Tuesday, June 3rd. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Perspective Therapeutics in a report on Monday, March 31st. B. Riley reissued a "buy" rating and set a $12.00 target price (up previously from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Finally, Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a research report on Saturday.

Perspective Therapeutics Price Performance

NYSE CATX traded up $0.18 during trading on Friday, hitting $4.08. 763,541 shares of the company traded hands, compared to its average volume of 1,087,378. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $16.55. The business has a fifty day simple moving average of $3.14 and a 200 day simple moving average of $2.88.

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. National Bank of Canada FI boosted its stake in Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after buying an additional 10,998 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after acquiring an additional 5,011 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Perspective Therapeutics in the fourth quarter valued at about $51,000. Corton Capital Inc. acquired a new position in Perspective Therapeutics in the fourth quarter worth about $61,000. Finally, Wexford Capital LP bought a new position in Perspective Therapeutics during the fourth quarter worth about $64,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.